Compare Stocks: ATYR, LUCD, NGEN, and KRRO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.43	$0.52	$0.40 ▼ $6.50	$42.16M	0.53	638,822 shs	1.41 million shs
KRRO Korro Bio	$13.81	$12.62	$5.20 ▼ $55.89	$203.42M	3.09	84,542 shs	197,974 shs
LUCD Lucid Diagnostics	$0.78	$0.96	$0.78 ▼ $1.63	$159.12M	1.1	862,394 shs	1.22 million shs
NGEN NervGen Pharma	$2.18 -0.5%	$1.89	$1.58 ▼ $6.30	$175.77M	N/A	602,773 shs	559,021 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	0.00%	-13.57%	-23.11%	-3.05%	-92.87%
KRRO Korro Bio	0.00%	+12.83%	+3.99%	+18.44%	-55.10%
LUCD Lucid Diagnostics	0.00%	-16.67%	-19.10%	-21.71%	-23.99%
NGEN NervGen Pharma	0.00%	-6.44%	+25.65%	+17.20%	+217,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.43	$0.52	$0.40 ▼ $6.50	$42.16M	0.53	638,822 shs	1.41 million shs
KRRO Korro Bio	$13.81	$12.62	$5.20 ▼ $55.89	$203.42M	3.09	84,542 shs	197,974 shs
LUCD Lucid Diagnostics	$0.78	$0.96	$0.78 ▼ $1.63	$159.12M	1.1	862,394 shs	1.22 million shs
NGEN NervGen Pharma	$2.18 -0.5%	$1.89	$1.58 ▼ $6.30	$175.77M	N/A	602,773 shs	559,021 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	0.00%	-13.57%	-23.11%	-3.05%	-92.87%
KRRO Korro Bio	0.00%	+12.83%	+3.99%	+18.44%	-55.10%
LUCD Lucid Diagnostics	0.00%	-16.67%	-19.10%	-21.71%	-23.99%
NGEN NervGen Pharma	0.00%	-6.44%	+25.65%	+17.20%	+217,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	2.25	Hold	N/A	N/A
KRRO Korro Bio	2.92	Moderate Buy	$16.71	21.03% Upside
LUCD Lucid Diagnostics	2.60	Moderate Buy	$4.19	434.87% Upside
NGEN NervGen Pharma	2.83	Moderate Buy	$14.00	542.20% Upside

Current Analyst Ratings Breakdown

Latest ATYR, LUCD, NGEN, and KRRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/18/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.50
8/13/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/4/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/4/2026	NGEN NervGen Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	NGEN NervGen Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/20/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	NGEN NervGen Pharma	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$10.00

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$190K	221.89	N/A	N/A	$0.69 per share	0.62
KRRO Korro Bio	$6.39M	31.83	N/A	N/A	$5.46 per share	2.53
LUCD Lucid Diagnostics	$4.71M	33.78	N/A	N/A	($0.31) per share	-2.53
NGEN NervGen Pharma	N/A	N/A	N/A	N/A	$0.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$74.12M	-$0.62	N/A	N/A	N/A	N/A	-95.89%	-69.67%	11/5/2026 (Estimated)
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	-1,834.48%	-114.26%	-68.57%	11/11/2026 (Estimated)
LUCD Lucid Diagnostics	-$58.01M	-$0.47	N/A	N/A	N/A	-959.76%	N/A	-119.57%	11/11/2026 (Estimated)
NGEN NervGen Pharma	-$31.58M	-$0.46	N/A	N/A	N/A	N/A	-1,259.82%	-199.79%	N/A

Latest ATYR, LUCD, NGEN, and KRRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	LUCD Lucid Diagnostics	-$0.0567	-$0.06	-$0.0033	-$0.08	$1.43 million	$1.47 million
8/13/2026	Q2 2026	NGEN NervGen Pharma	-$0.09	-$0.37	-$0.28	-$0.37	N/A	N/A
8/7/2026	Q2 2026	ATYR aTyr Pharma	-$0.1214	-$0.11	+$0.0114	-$0.11	N/A	$189.56 million
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
NGEN NervGen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	N/A	5.12	5.12
KRRO Korro Bio	N/A	9.55	9.55
LUCD Lucid Diagnostics	N/A	1.33	1.31
NGEN NervGen Pharma	N/A	1.23	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
KRRO Korro Bio	13.18%
LUCD Lucid Diagnostics	74.01%
NGEN NervGen Pharma	N/A

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	5.75%
KRRO Korro Bio	4.80%
LUCD Lucid Diagnostics	6.90%
NGEN NervGen Pharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	98.09 million	92.45 million	Optionable
KRRO Korro Bio	70	14.73 million	14.02 million	No Data
LUCD Lucid Diagnostics	70	203.24 million	189.22 million	No Data
NGEN NervGen Pharma	N/A	80.63 million	N/A	N/A

ATYR, LUCD, NGEN, and KRRO Headlines

Recent News About These Companies

NervGen to Host Inaugural R&D Day on September 30, 2026

September 9, 2026 | globenewswire.com

NervGen Pharma (NASDAQ:NGEN) Given Average Recommendation of "Moderate Buy" by Analysts

August 25, 2026 | marketbeat.com

Empery Asset Management LP Invests $8.24 Billion in NervGen Pharma $NGEN

August 22, 2026 | marketbeat.com

NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

NervGen Pharma Corp.: NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 13, 2026 | finanznachrichten.de

NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position

August 13, 2026 | tipranks.com

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 13, 2026 | globenewswire.com

NervGen Pharma (NGEN) Gains Ground: Biotech Stock Holds Above Key Support - Iron Condor Alert

July 14, 2026 | donanimhaber.comD

NervGen Pharma Corp. : NGEN

July 13, 2026 | 247wallst.com

NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners

July 2, 2026 | tipranks.com

NervGen Pharma: I Think The Biggest Risks Are Now Behind It

July 2, 2026 | seekingalpha.com

NervGen rises as TD Cowen issues new Buy on lead asset

June 11, 2026 | seekingalpha.com

NGEN Share News Today

June 10, 2026 | uk.investing.com

NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program

June 1, 2026 | tipranks.com

NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3

May 26, 2026 | tipranks.com

Why Is NervGen Pharma Stock Gaining Tuesday?

May 26, 2026 | benzinga.com

NervGen Pharma Reports Positive Biomechanical Gait Analysis Results for NVG-291 Demonstrating Genuine Neural Recovery in Chronic Tetraplegia

May 26, 2026 | quiverquant.comQ

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

May 26, 2026 | globenewswire.com

NervGen Pharma Rings the Nasdaq Stock Market Closing Bell

May 25, 2026 | nasdaq.com

NervGen Pharma (NGEN) Receives a Buy from Stifel Nicolaus

May 25, 2026 | theglobeandmail.com

NervGen Pharma stock tumbles on dilutive share offering

May 22, 2026 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, LUCD, NGEN, and KRRO Company Descriptions

aTyr Pharma NASDAQ:ATYR

$0.43 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.43 +0.00 (+0.05%)

As of 09/11/2026 07:59 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Korro Bio NASDAQ:KRRO

$13.81 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$13.84 +0.03 (+0.18%)

As of 04:25 AM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Lucid Diagnostics NASDAQ:LUCD

$0.78 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.79 +0.00 (+0.52%)

As of 05:31 AM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

NervGen Pharma NASDAQ:NGEN

$2.18 -0.01 (-0.46%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.22 +0.04 (+2.06%)

As of 04:00 AM Eastern

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATYR, LUCD, NGEN, and KRRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATYR, LUCD, NGEN, and KRRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATYR, LUCD, NGEN, and KRRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, LUCD, NGEN, and KRRO Company Descriptions

aTyr Pharma NASDAQ:ATYR

Korro Bio NASDAQ:KRRO

Lucid Diagnostics NASDAQ:LUCD

NervGen Pharma NASDAQ:NGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATYR, LUCD, NGEN, and KRRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATYR, LUCD, NGEN, and KRRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATYR, LUCD, NGEN, and KRRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, LUCD, NGEN, and KRRO Company Descriptions

aTyr Pharma NASDAQ:ATYR

Korro Bio NASDAQ:KRRO

Lucid Diagnostics NASDAQ:LUCD

NervGen Pharma NASDAQ:NGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools